E2211: Dr. Pamela Kunz discusses the trial results and talks about the challenges of managing endocrine tumors
The Video Journal of Oncology (VJ Oncology)
Patients with advanced progressive pancreatic neuroendocrine tumors (NETs) have few treatment options. The E2211 randomized phase II trial shows the most prolonged progression-free survival reported for patients with these tumors. Recently, study chair Pamela L. Kunz, MD (Yale University School of Medicine), described the challenges of treating patients with pancreatic NETS.
Dr. Kunz also discussed the E2211 final analysis of efficacy and evaluation of MGMT as a predictive biomarker.